Moreover, several groups have substantiated the role of neoantigens in response to ICIs, supported by evidence of higher neoantigen load being associated with better therapeutic response to CTLA-4 and PD-1 blockade in patients with melanoma and non-small-lung cancer [18,19,20]. The gene discussed is CTLA4; the disease is melanoma.